Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRY-371797 in LMNA-Related Dilated Cardiomyopathy
NCT03439514Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of emprumapimod in dilated cardiomyopathy (DCM) (3 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Six-Minute Walk Test at 24 weeks. Started Apr 2018; status: terminated.
02
Drugs
emprumapimod
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT03439514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439514.